Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTNM Stock Forecast 2025-2026
$3.65
Current Price
$110.99M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CTNM Price Targets
+749.3%
To High Target of $31.00
+530.1%
To Median Target of $23.00
+338.4%
To Low Target of $16.00
CTNM Price Momentum
-17.6%
1 Week Change
-4.7%
1 Month Change
-81.5%
1 Year Change
-75.1%
Year-to-Date Change
-83.4%
From 52W High of $22.00
+9.0%
From 52W Low of $3.35
📊 TOP ANALYST CALLS
Did CTNM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Contineum Therapeutics is one of their latest high-conviction picks.
Latest CTNM Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CTNM has a bullish consensus with a median price target of $23.00 (ranging from $16.00 to $31.00). Currently trading at $3.65, the median forecast implies a 530.1% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brian Abrahams at RBC Capital, projecting a 749.3% upside. Conversely, the most conservative target is provided by Joel Beatty at Baird, suggesting a 338.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTNM Analyst Ratings
5
Buy
0
Hold
0
Sell
CTNM Price Target Range
Low
$16.00
Average
$23.00
High
$31.00
Current: $3.65
Latest CTNM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTNM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $20.00 |
| May 15, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $31.00 |
| Mar 13, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $23.00 |
| Mar 7, 2025 | Baird | Joel Beatty | Outperform | Maintains | $16.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $25.00 |
| Jan 9, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $31.00 |
| Nov 7, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $31.00 |
| Oct 22, 2024 | Baird | Joel Beatty | Outperform | Initiates | $32.00 |
| Aug 14, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $32.00 |
| Apr 30, 2024 | Stifel | Paul Matteis | Buy | Initiates | $29.00 |
| Apr 30, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Initiates | $25.00 |
| Apr 30, 2024 | RBC Capital | Brian Abrahams | Outperform | Initiates | $30.00 |
Continua Therapeutics Inc. (CTNM) Competitors
The following stocks are similar to Contineum Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CTNM
Contineum Therapeutics
mkt cap
117.20M
Continua Therapeutics Inc. (CTNM) Financial Data
Continua Therapeutics Inc. has a market capitalization of $110.99M with a P/E ratio of 26.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -33.0%.
Valuation Metrics
Market Cap
$110.99M
Enterprise Value
$-83,032,816
P/E Ratio
26.0x
PEG Ratio
-2.1x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+201.9%
Current Ratio
21.5x
Debt/Equity
3.2x
ROE
-33.0%
ROA
-22.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Continua Therapeutics Inc. (CTNM) Business Model
About Continua Therapeutics Inc.
What They Do
Biotechnology company developing innovative therapeutic solutions.
Business Model
Continua Therapeutics Inc. generates revenue through the development and commercialization of novel drug candidates targeting unmet medical needs. The company focuses on research and development in fields such as oncology, neurology, and autoimmune disorders, leveraging strategic collaborations to enhance its pipeline and market presence.
Additional Information
The company aims to pioneer next-generation pharmaceuticals that could change standard treatment protocols, positioning itself as a significant player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
41
CEO
Mr. Carmine N. Stengone MBA, MS
Country
United States
IPO Year
2024
Website
www.contineum-tx.comContinua Therapeutics Inc. (CTNM) Latest News & Analysis
Latest News
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
1 month ago
Quick Summary
Contineum Therapeutics, Inc. (NASDAQ: CTNM) will present at the 2025 RBC Capital Markets Global Healthcare Conference on May 20 at 8:30 a.m. ET. An audio webcast will be available online.
Why It Matters
Contineum Therapeutics' presentation at a major healthcare conference could attract investor interest in its innovative therapies, potentially impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Contineum Therapeutics (NASDAQ: CTNM) reported Q1 2025 financial results, confirming progress on clinical development milestones in neuroscience, inflammation, and immunology.
Why It Matters
Contineum Therapeutics' solid Q1 2025 results and commitment to clinical milestones signal potential growth and innovation, affecting investor confidence and stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Contineum Therapeutics appointed Dr. Timothy Watkins as Chief Medical Officer and Head of Development, effective immediately, to lead clinical development in neuroscience, inflammation, and immunology.
Why It Matters
The appointment of Dr. Timothy Watkins as CMO may enhance Contineum's clinical strategy and development, potentially accelerating drug advancements and impacting future stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
3 months ago
Quick Summary
Contineum Therapeutics, Inc. (NASDAQ: CTNM) appointed Dr. Diego Miralles to its board of directors, effective March 14, 2025, enhancing its leadership in neuroscience and immunology therapies.
Why It Matters
The appointment of Dr. Diego Miralles to Contineum's board signals potential strategic advancements in their clinical-stage therapies, which could influence company performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Contineum Therapeutics, Inc. (NASDAQ: CTNM) will present at the Stifel 2025 Virtual CNS Forum on March 18th at 12:30 p.m. ET. An audio webcast will be available on their website.
Why It Matters
Contineum's presentation at a prominent CNS forum could signal potential advancements in their therapies, impacting stock performance and investor sentiment in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
3 months ago
Quick Summary
Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported its Q4 2024 financial results and highlighted key clinical milestones for 2025, anticipating significant data readouts and trial initiations.
Why It Matters
Contineum's financial results and upcoming clinical milestones signal potential growth and investment opportunities, particularly in the promising fields of neuroscience and immunology.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CTNM Stock
What is Continua Therapeutics Inc.'s (CTNM) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Continua Therapeutics Inc. (CTNM) has a median price target of $23.00. The highest price target is $31.00 and the lowest is $16.00.
Is CTNM stock a good investment in 2025?
According to current analyst ratings, CTNM has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTNM stock?
Wall Street analysts predict CTNM stock could reach $23.00 in the next 12 months. This represents a 530.1% increase from the current price of $3.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Continua Therapeutics Inc.'s business model?
Continua Therapeutics Inc. generates revenue through the development and commercialization of novel drug candidates targeting unmet medical needs. The company focuses on research and development in fields such as oncology, neurology, and autoimmune disorders, leveraging strategic collaborations to enhance its pipeline and market presence.
What is the highest forecasted price for CTNM Continua Therapeutics Inc.?
The highest price target for CTNM is $31.00 from Brian Abrahams at RBC Capital, which represents a 749.3% increase from the current price of $3.65.
What is the lowest forecasted price for CTNM Continua Therapeutics Inc.?
The lowest price target for CTNM is $16.00 from Joel Beatty at Baird, which represents a 338.4% increase from the current price of $3.65.
What is the overall CTNM consensus from analysts for Continua Therapeutics Inc.?
The overall analyst consensus for CTNM is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $23.00.
How accurate are CTNM stock price projections?
Stock price projections, including those for Continua Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 7:07 PM UTC